Zobrazeno 1 - 10 of 1 121 pro vyhledávání: '"Gatell, Jm"'
1
Akademický článek
Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial
Autor: Ajana, F, Arribas, JR, Bailey, J, Benson, P, Berenguer, J, Bhatti, L, Blaxhult, A, Brar, I, Bredeek, UF, Brinson, C, Brunetta, J, Casado, J, Clarke, A, Conway, B, Cotte, L, Crofoot, G, Cunningham, D, de Vente, J, De Wit, S, DeJesus, E, Dietz, C, Dretler, R, Eron, J, Fehr, J, Felizarta, F, Fichtenbaum, C, Flamholc, L, Florence, E, Galindo, MJ, Gallant, J, Gasiorowski, J, Gatell, JM, Gathe, J, Gazzard, BG, Girard, P-M, Gisslèn, M, Gutierrez, F, Gutierrez, MDM, Hagins, D, Halota, W, Henn, S, Henry, WK, Horban, A, Huhn, G, Iribarren, JA, Jain, M, Johnson, MA, Katlama, C, Klein, M, Knobel, H, Lucasti, C, Martorell, C, McDonald, C, Mills, A, Molina, J-M, Morales-Ramirez, J, Mounzer, K, Moutschen, M, Murphy, D, Nahass, R, Negredo, E, Olivet, H, Orkin, C, Osiyemi, O, Perez-Valero, I, Piekarska, A, Pineda, JA, Podzamczer, D, Poizot-Martin, I, Portilla Sogorb, J, Post, F, Prelutsky, D, Pulido, F, Rachlis, A, Raffi, F, Ramgopal, M, Rashbaum, B, Rauch, A, Rey, D, Reynes, J, Ricart, C, Richmond, G, Rivero, A, Ruane, P, Gil, I Santos, Scarsella, A, Scribner, A, Shafran, S, Shalit, P, Shamblaw, D, Slim, J, Stoeckle, M, Tashima, K, Teicher, E, Thalme, A, Ustianowski, A, Van Wijngaerden, E, Vandekerckhove, L, Vandercam, B, Voskuhl, G, Walmsley, S, Ward, D, Waters, L, Wilkin, A, Witor, A, Yazdanpanah, Y, Orkin, Chloe, Molina, Jean-Michel, Negredo, Eugenia, Arribas, José R, Gathe, Joseph, Eron, Joseph J, Van Landuyt, Erika, Lathouwers, Erkki, Hufkens, Veerle, Petrovic, Romana, Vanveggel, Simon, Opsomer, Magda
Publikováno v: In The Lancet HIV January 2018 5(1):e23-e34
Zobrazit plný text záznamu
2
Akademický článek
Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial
Autor: Cahn, PE, Cassetti, I, Losso, M, Bloch, MT, Roth, N, McMahon, J, Moore, RJ, Smith, D, Clumeck, N, Vanderkerckhove, L, Vandercam, B, Moutschen, M, Baril, J, Conway, B, Smaill, F, Smith, GHR, Rachlis, A, Walmsley, SL, Perez, C, Wolff, M, Lasso, MF, Chahin, CE, Velez, JD, Sussmann, O, Reynes, J, Katlama, C, Yazdanpanah, Y, Ferret, S, Durant, J, Duvivier, C, Poizot-Martin, I, Ajana, F, Rockstroh, JK, Faetkanheuer, G, Esser, S, Jaeger, H, Degen, O, Bickel, M, Bogner, J, Arasteh, K, Hartl, H, Stoehr, A, Rojas, EM, Arathoon, E, Gonzalez, LD, Mejia, CR, Shahar, E, Turner, D, Levy, I, Sthoeger, Z, Elinav, H, Gori, A, Monforte, A D'Arminio, Di Perri, G, Lazzarin, A, Rizzardini, G, Antinori, A, Celesia, BM, Maggiolo, F, Chow, TS, Lee, CKC, Azwa, R Iskandar Shah Raja, Mustafa, M, Oyanguren, M, Castillo, RA, Hercilla, L, Echiverri, C, Maltez, F, da Cunha, JG Saraiva, Neves, I, Teofilo, E, Serrao, R, Nagimova, F, Khaertynova, I, Orlova-Morozova, E, Voronin, E, Sotnikov, V, Yakovlev, AA, Zakharova, NG, Tsybakova, OA, Botes, ME, Mohapi, L, Kaplan, R, Rassool, MS, Arribas, JR, Gatell, JM, Negredo, E, Ortega, E, Troya, J, Berenguer, J, Aguirrebengoa, K, Antela, A, Calmy, A, Cavassini, M, Rauch, A, Stoeckle, M, Sheng, WH, Lin, HH, Tsai, HC, Changpradub, D, Avihingsanon, A, Kiertiburanakul, S, Ratanasuwan, W, Nelson, MR, Clarke, A, Ustianowski, A, Winston, A, Johnson, MA, Asmuth, DM, Cade, J, Gallant, JE, Ruane, PJ, Kumar, PN, Luque, AE, Panther, L, Tashima, KT, Ward, D, Berger, DS, Dietz, CA, Fichtenbaum, C, Gupta, S, Mullane, KM, Novak, RM, Sweet, DE, Crofoot, GE, Hagins, DP, Lewis, ST, McDonald, CK, DeJesus, E, Sloan, L, Prelutsky, DJ, Rondon, JC, Henn, S, Scarsella, AJ, Morales, JO, Ramirez, Santiago, L, Zorrilla, CD, Saag, MS, Hsiao, CB, Cahn, Pedro, Kaplan, Richard, Sax, Paul E, Squires, Kathleen, Molina, Jean-Michel, Avihingsanon, Anchalee, Ratanasuwan, Winai, Rojas, Evelyn, Rassool, Mohammed, Bloch, Mark, Vandekerckhove, Linos, Ruane, Peter, Yazdanpanah, Yazdan, Katlama, Christine, Xu, Xia, Rodgers, Anthony, East, Lilly, Wenning, Larissa, Rawlins, Sandy, Homony, Brenda, Sklar, Peter, Nguyen, Bach-Yen, Leavitt, Randi, Teppler, Hedy
Publikováno v: In The Lancet HIV November 2017 4(11):e486-e494
Zobrazit plný text záznamu
3
Impact of switching to raltegravir and/or adding losartan in lymphoid tissue fibrosis and inflammation in people living with HIV. A randomized clinical trial
Autor: Gatell Jm, Lorna Leal, M Squarcia, A Fabra, Berta Torres, Alba Díaz, Alberto C. Guardo, M. Plana, A Ugarte, Felipe García, Miguel Caballero
Publikováno v: HIV Medicine. 22:674-681
Background Persistent inflammation and immune activation are associated with lymph node fibrosis and end-organ diseases in treatment-suppressed people living with HIV (PLWH). We investigated the effect of switching to raltegravir and/or adding losart
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::58a03a2f1612441aa58f9de105bc77c4
https://doi.org/10.1111/hiv.13114
Zobrazit plný text záznamu
4
Efficacy and safety of switching to dolutegravir plus lamivudine versus continuing triple antiretroviral therapy in virologically suppressed adults with HIV at 48 weeks (DOLAM): a randomised non-inferiority trial
Autor: Rojas, J, de Lazzari, E, Negredo, E, Domingo, P, Tiraboschi, J, Ribera, E, Abdulghani, N, Puig, J, Mateo, MG, Podzamczer, D, Gutierrez, MM, Paredes, R, Clotet, B, Gatell, JM, Blanco, JL, Martinez, E, DOLAM Study Grp
Publikováno v: Lancet HIV
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
Background Simplified antiretroviral therapy (ART) regimens are desirable for people with HIV. We investigated the efficacy and safety of switching from triple ART to dual dolutegravir plus lamivudine therapy. Methods DOLAM is a phase 4, randomised,
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=RECOLECTA___::b8ca5092754664ac0f72c87171e8f1a1
https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=5511
Zobrazit plný text záznamu
5
Switching from boosted PIs to dolutegravir in HIV-infected patients with high cardiovascular risk: 48 week effects on subclinical cardiovascular disease
Autor: Gonzalez-Cordon, A, Assoumou, L, Camafort, M, Domenech, M, Guaraldi, G, Domingo, P, Rusconi, S, Raffi, F, Katlama, C, Masia, M, Bernardino, JI, Saumoy, M, Pozniak, A, Gatell, JM, Martinez, E, NEAT022 Study Grp
Publikováno v: JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
instname
r-FISABIO: Repositorio Institucional de Producción Científica
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
r-FISABIO. Repositorio Institucional de Producción Científica
r-IIB SANT PAU: Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
Background: Switching from boosted PIs to dolutegravir in virologically suppressed HIV-infected patients with high cardiovascular risk significantly decreased total cholesterol and other proatherogenic Lipid fractions at 48 weeks. The impact of this
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::120aa51e704bbbe491d9630dd3dc625c
https://fundanet.isabial.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=7057
Zobrazit plný text záznamu
7
Subclinical cardiovascular disease in patients starting contemporary protease inhibitors
Autor: E de Lazzari, Esteban Martínez, Jhon Rojas, María Martínez-Rebollar, Gatell Jm, Mónica Doménech, José Mallolas, José Luis Santiago Blanco, Montserrat Lonca, Miguel Camafort, Berta Torres, Montserrat Laguno, Ana González-Cordón
Publikováno v: HIV Medicine. 19:497-503
OBJECTIVES The aim of the study was to assess changes in and factors associated with anatomical [carotid artery intima-media thickness (CIMT)] and functional (arterial stiffness) markers of subclinical cardiovascular disease progression in antiretrov
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d2330c39e92c86a9a6cb06004ca58127
https://doi.org/10.1111/hiv.12619
Zobrazit plný text záznamu
9
Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1
Autor: Douglas Cunningham, D. Ward, Mamta K. Jain, Faiza Ajana, Magda Opsomer, Anita Rachlis, Sharon Walmsley, Frank A. Post, Anders Blaxhult, Amanda Clarke, M. J. Galindo, Marcel Stoeckle, P.-M. Girardy, Karam Mounzer, David Shamblaw, U. F. Bredeek, L. Bhatti, J. J. Eron, Andrew Ustianowski, Mar Gutierrez, John Jezorwski, Javier O Morales-Ramirez, Antonio Rivero, M.A. Johnson, Gatell Jm, Erika Van Landuyt, Stéphane De Wit, A. Wilkin, Laurent Cotte, Cheryl McDonald, D. Murphy, Cynthia Brinson, Romana Petrovic, Olayemi Osiyemi, J. de Vente, I. Poizot-Martin, Juan Berenguer, Robin Dretler, J. Bailey, B. Rashbaum, Moti Ramgopal, A. Scribner, Yazdan Yazdanpanah, Eric Florence, A. Piekarska, Brian Gazzard, Chloe Orkin, W. Halota, Gary Richmond, Jacques Reynes, C. Ricart, C. Lucasti, Ignacio Pérez-Valero, Jason Brunetta, S. Shafran, Daniel Podzamczer, Franco Antonio Felizarta, Claudia Martorell, F. Post, Peter Ruane, Edwin DeJesus, J. Portilla Sogorb, C. Orkin, K. Tashima, Federico Pulido, Bernard Vandercam, F. Pulido, José L. Casado, Christine Katlama, Kimberley Brown, J Gasiorowski, A. Witor, Joseph J. Eron, Brian Conway, Andri Rauch, Jose R. Arribas, Michel Moutschen, H. Olivet, A. Scarsella, Leo Flamholc, A. Horban, D. Cunningham, Ronald Nahass, Félix Gutiérrez, G. Huhn, W.K. Henry, A. Thalme, S De Wit, Jan Fehr, Debbie Hagins, José Antonio Iribarren, J.-M. Molina, S. Henn, F Raffi, Juan A. Pineda, Marina B. Klein, Eugenia Negredo, Hernando Knobel, J. Slim, P. Benson, L. Waters, E. Teicher, Linos Vandekerckhove, Craig A. Dietz, Magnus Gisslén, Joel E. Gallant, J. Gathe, P. Shalit, D. Prelutsky, G. Voskuhl, D. Rey, E. Van Wijngaerden, Anthony Mills, Erkki Lathouwers, Carl J. Fichtenbaum, I. Brar, Gordon Crofoot, Veerle Hufkens, I. Santos Gil
Publikováno v: Antiviral Research
Antiviral Research, Elsevier Masson, 2019, 170, pp.104543. ⟨10.1016/j.antiviral.2019.104543⟩
ANTIVIRAL RESEARCH
Antiviral Research, 2019, 170, pp.104543. ⟨10.1016/j.antiviral.2019.104543⟩
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
Dipòsit Digital de la UB
Universidad de Barcelona
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
Antiviral research, Vol. 170, p. 104543 [1-11] (2019)
Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) 800/150/200/10 mg was investigated through 96 weeks in EMERALD (NCT02269917). Virologically-suppressed, HIV-1-positive treatment-experienced adults (previous non-darunavir virologic
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::017eb51bc97390ae19e12fb2aea5fdc8
http://hdl.handle.net/2445/171213
Zobrazit plný text záznamu
10
Determinants and Outcomes of Late Presentation of HIV Infection in Migrants in Catalonia, Spain: PISCIS Cohort 2004-2016
Autor: Conway, AS, Esteve, A, Fernandez-Quevedo, M, Casabona, J, Miro, JM, Riera, AB, Montoliu, A, Reyes, J, Muntada, E, Bruguera, A, Podzamczer, D, Domingo, P, Llibre, JM, Riera, S, Navarro, G, Cortes, C, Falco, V, Gatell, JM, Manzardo, C, Clotet, B, Ferrer, E, Segura, F, Force, L, Vilaro, J, Masabeu, A, Leon, E, Cifuentes, C, Homar, F, Dalmau, D, Jaen, A, Mateo, MG, Gutierrez, MD, Loureiro, E, Curran, A, Puig, T, Agusti, C, Vidal, F, Peraire, J, Orti, A, Almuedo, A, De Lazzari, E, Giralt, D, Gargoulas, F, Rubia, JC, Vila, J, Ambrosioni, J, Zamora, L, Blanco, JL, Garcia-Alcaide, F, Martinez, E, Mallolas, J, Sirera, G, Romeu, J, Jou, A, Negredo, E, Saumoy, M, Imaz, A, Bolao, F, Cabellos, C, Pena, C, DiYacovo, S, Van Den Eynde, E, Sala, M, Cervantes, M, Amengual, MJ, Navarro, M, Segura, V, Barrufet, P, Payeras, T, Gurgui, M, Utrillo, L, Meyer, S, Hernandez, J
Publikováno v: Journal of Immigrant and Minority Health
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
This study using the Catalan PISCIS cohort explores risk factors of migrants' late presentation and the impact of late presentation on their health outcomes. We analyse 9590 new HIV diagnoses enrolled in the cohort between 2004 and 2016. Univariate a
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=RECOLECTA___::759fb29d47b3d363dca05c0973e91358
https://fundanet.igtp.cat/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=2809
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje